Alerts will be sent to your verified email
Verify Email
PPLPHARMA
|
Piramal Pharma
|
Cohance Lifesciences
|
Suven Life Sciences
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Domestic Sales Growth - YoY
|
15.43 % | n/a | n/a |
|
R&D as a % of Total Sales
|
0.14 % | 4.19 % | 2132.75 % |
|
Financials
|
|||
|
5 yr Average ROE
|
3.82 % | 22.91 % | -82.05 % |
|
5yr average Equity Multiplier
|
1.94 | 1.35 | 1.55 |
|
5yr Average Asset Turnover Ratio
|
0.55 | 0.56 | 0.05 |
|
5yr Avg Net Profit Margin
|
3.51 % | 30.38 % | -1150.51 % |
|
Price to Book
|
3.41 | 20.51 | 46.36 |
|
P/E
|
282.33 | 135.92 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
-19.3 Days | 49.95 Days | 97.84 Days |
|
Inventory Days
|
70.13 Days | 74.21 Days | 10.88 Days |
|
Days Receivable
|
77.05 Days | 63.71 Days | 71.91 Days |
|
Days Payable
|
159.9 Days | 80.35 Days | 3.38 Days |
|
5yr Average Interest Coverage Ratio
|
2.86 | 49.87 | -373.47 |
|
5yr Avg ROCE
|
6.75 % | 27.5 % | -82.34 % |
|
5yr Avg Operating Profit Margin
|
15.15 % | 40.14 % | -1227.3 % |
|
5 yr average Debt to Equity
|
0.62 | 0.06 | 0.0 |
|
5yr CAGR Net Profit
|
-35.79 % | -5.86 % | 17.38 % |
|
5yr Average Return on Assets
|
2.03 % | 17.54 % | -54.63 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
34.86 % | 66.41 % | 70.27 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.07 % | 6.41 % | 5.29 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
11.78 % | 2.58 % | 0.0 |
|
Piramal Pharma
|
Cohance Lifesciences
|
Suven Life Sciences
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Services Break-Up
|
Services Break-Up
|
-
|
-
|